Connect with us

Technology

BionicM Announces Launch of U.S. Headquarters and Unveils Bio Leg®, Awarded CES 2025 Best of Innovation

Published

on

TOKYO, Jan. 7, 2025 /PRNewswire/ — BionicM (CEO: Sunny Xiaojun Sun, Ph.D) is thrilled to announce the launch of its U.S. subsidiary, BionicM USA, located in the Virginia area near Washington, D.C. This strategic move reinforces the company’s commitment to delivering advanced powered microprocessor knee solutions to the world’s largest prosthetics market.

BionicM is proud to introduce its flagship product, the Bio Leg®, an innovative powered microprocessor knee that has garnered prestigious recognition as a CES 2025 Best of Innovation winner. Following successful PDAC insurance coverage approval in May 2024, the Bio Leg was launched in the U.S. market in summer 2024, meeting revenue expectations.

The new U.S. office will serve as the operational hub, enhancing inventory capabilities to reduce delivery lead times and accelerate sales efforts. It will also ensure comprehensive after-sales service for prosthetics practitioners and patients, reflecting BionicM’s commitment to excellence in service.

Recognizing the significant growth potential in the U.S. prosthetics market, BionicM USA is well-positioned to meet the increasing demand for powered prosthetic solutions. The opening of the U.S. office symbolizes the company’s dedication to providing high-quality products and exceptional service. Notable achievements leading up to this launch include the first delivery of the Bio Leg to U.S. customers in September 2024 and securing $3 million in fundraising in September 2024.

BionicM looks forward to serving the U.S. market and continuing to innovate in the field of prosthetic solutions.

Bio Leg: Awarded CES 2025 Best of Innovation and Showcased at CES 2025
BionicM’s Bio Leg has been honored as a CES 2025 Best of Innovation winner, showcasing its exceptional design and engineering. At CES 2025, held from January 7-10 in Las Vegas, BionicM will proudly showcase this groundbreaking technology at the J-Startup/JAPAN Pavilion in Eureka Park (Booth No. 61000 & 61001, Tech West, Venetian Expo, Level 1, Hall G). This event not only highlights the transformative potential of powered prosthetics but also provides a unique opportunity to connect with industry leaders.

Join us at CES 2025 to experience firsthand how Bio Leg is setting new standards in prosthetic technology and transforming lives.

About Bio Leg: Transforming Lives Through Advanced Robotics

The Bio Leg powered microprocessor knee revolutionizes mobility by replacing lost muscle strength with advanced robotics technology. This innovative solution reduces physical strain and promotes natural, intuitive movement, empowering users to engage in active lifestyles and significantly enhancing their overall quality of life.

After extensive trials involving over 300 participants, the Bio Leg received FDA Class II medical device registration in July 2023 and U.S. medical insurance coverage approval in May 2024. Users have praised its seamless integration with their movements, highlighting its combination of safety, ease of use, and life-changing capabilities.

About BionicM:Pioneering Mobility Solutions through Robotics and Human Physiology

Founded in 2018 as a spin-off from the University of Tokyo, BionicM emerged from the innovative research and development spearheaded by Sunny Xiaojun Sun during his doctoral studies at the University of Tokyo, under the mentorship of Professor Inaba (currently Professor Emeritus). Supported by JST’s START program, BionicM leverages advanced humanoid robotics technology to develop and market powered microprocessor knees.

As a global startup, BionicM is driven by its mission to “Power Mobility for All,” with a focus on enhancing mobility and improving the quality of life (QOL) for individuals with lower-limb amputations. Through cutting-edge technology and a commitment to innovation, BionicM aims to provide transformative solutions that empower users to lead more active and fulfilling lives.

Japan Headquarters: Entrepreneur Plaza 203, University of Tokyo, 7-3-1 Hongo, Bunkyo, Tokyo
USA Headquarters: 20130 Lakeview Center Plaza, Ashburn, VA 20147
URL: https://bionicm.com/

Contact: Naoko Kita
e-mail: 388410@email4pr.com
Phone: +81-3-3868-2679

View original content to download multimedia:https://www.prnewswire.com/news-releases/bionicm-announces-launch-of-us-headquarters-and-unveils-bio-leg-awarded-ces-2025-best-of-innovation-302344370.html

SOURCE BionicM Inc.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

TriNetX’s Founding CEO Announces Plans to Step Down

Published

on

By

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board

CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ — TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company’s Founder, President and CEO, will step down from his operating role on March 31, 2025. Gadi founded TriNetX in 2014 and has served as President and CEO in the succeeding 11 years. Gadi will continue to serve on TriNetX’s Board of Directors and will be an Advisor to Carlyle, TriNetX’s majority investor.

“It has been an honor to build TriNetX and be part of such an outstanding team. I want to thank TriNetX’s employees, customers, and shareholders for the support they have shown me. With the talent and passion of our people I am immensely confident in TriNetX’s continued success,” said Lachman. “Together, we have built the largest global platform for clinical research, with data from over 25 countries and tens of millions of queries a month. Our solutions are moving clinical research to a whole different level and saving lives on a massive scale, across all therapeutic areas.”

During the transition period, Jeff Margolis, a current TriNetX Director, will serve as Executive Chairman to ensure continuity in leadership and governance while a CEO search is conducted.

Margolis said, “I have had the distinct privilege of serving on the Board alongside Gadi and partnering with him for 11 years. On behalf of the Board, we thank Gadi for shaping and leading TriNetX to become the world’s top ecosystem of real-world data and real-world evidence serving life sciences and the broader healthcare industry. I look forward to working with him and the rest of the Board over the next months to execute a successful transition of leadership.”

Joe Bress, Partner and Global Co-Head of Healthcare for Carlyle, TriNetX’s lead investor, added, “We have been thrilled to partner with Gadi since our initial investment in TriNetX over four years ago. Thanks to his disciplined leadership, TriNetX is one of the few companies that has sustained profitability even during periods of high growth. Gadi has built the company up to an exciting point, paving the way for a new leader to take the business into its next chapter of growth and success.”

Through this leadership transition, TriNetX remains steadfast in its mission to advance global healthcare through the power of real-world data. The Board, leadership team, and employees are united in their commitment to driving continued innovation and delivering success for customers and partners, all while building on Gadi’s exceptional legacy.

About TriNetX, LLC

TriNetX is a global network of healthcare organizations and life sciences companies dedicated to advancing real-world research and expediting the development of new therapies. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn.

Media Contact
TriNetX
Michelle Fleming, Chief Marketing Officer
Email: Michelle.Fleming@TriNetX.com

Logo – https://mma.prnewswire.com/media/542641/TriNetX_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/trinetxs-founding-ceo-announces-plans-to-step-down-302347367.html

Continue Reading

Technology

Stellus Private Credit BDC Announces $0.36 First Quarter 2025 Regular Dividend, Payable Monthly in Increments of $0.12 in January, February, and March 2025

Published

on

By

HOUSTON, Jan. 9, 2025 /PRNewswire/ — Stellus Private Credit BDC (“the Company”) announced that its Board of Trustees has declared a monthly dividend of $0.12 for each of January, February, and March, totaling $0.36 per share in the aggregate for the first quarter of 2025. The regular dividend of $0.36 per share will be paid to shareholders of record in January, February, and March 2025.

Summary of First Quarter 2025 Regular Monthly Dividends

Declared

Record Date

Payment Date

Amount per Share

1/9/2025

1/10/2025

1/31/2025

$0.12

1/9/2025

2/3/2025

2/28/2025

$0.12

1/9/2025

3/3/2025

3/31/2025

$0.12

About Stellus Private Credit BDC

The Company is an externally-managed, closed-end, non-diversified investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing primarily in private middle-market companies (typically those with $5.0 million to $50.0 million of EBITDA (earnings before interest, taxes, depreciation and amortization)) through first lien (including unitranche) loans, second lien loans and unsecured debt financing, with corresponding equity co-investments. The Company’s investment activities are managed by its investment adviser, Stellus Private BDC Advisor, LLC.

Forward-Looking Statements

Statements included herein may contain “forward-looking statements” which relate to future performance or financial condition. Statements other than statements of historical facts included in this press release, including statements about COVID-19 and its impacts, may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of assumptions, risks and uncertainties, which change over time. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission including the final prospectus that will be filed with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Contacts
Stellus Private Credit BDC
W. Todd Huskinson, Chief Financial Officer
(713) 292-5414
thuskinson@stelluscapital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/stellus-private-credit-bdc-announces-0-36-first-quarter-2025-regular-dividend-payable-monthly-in-increments-of-0-12-in-january-february-and-march-2025–302347311.html

SOURCE Stellus Private Credit BDC

Continue Reading

Technology

MongoDB, Inc. to Present at the 27th Annual Needham Growth Conference

Published

on

By

NEW YORK, Jan. 9, 2025 /PRNewswire/ — MongoDB, Inc. (NASDAQ: MDB) today announced that Chief Operating Officer and Chief Financial Officer, Michael Gordon, and Senior Vice President of Finance, Serge Tanjga, will present virtually at the 27th Annual Needham Growth Conference.

The MongoDB presentation is scheduled for Thursday, January 16, 2025, at 3:45 p.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the MongoDB investor relations website at https://investors.mongodb.com/news-events/events. A replay of the webcast will also be available for a limited time.

About MongoDB
Headquartered in New York, MongoDB’s mission is to empower innovators to create, transform, and disrupt industries by unleashing the power of software and data. Built by developers, for developers, MongoDB’s developer data platform is a database with an integrated set of related services that allow development teams to address the growing requirements for today’s wide variety of modern applications, all in a unified and consistent user experience. MongoDB has tens of thousands of customers in over 100 countries. The MongoDB database platform has been downloaded hundreds of millions of times since 2007, and there have been millions of builders trained through MongoDB University courses. To learn more, visit mongodb.com.

Investor Relations
Brian Denyeau
ICR for MongoDB
646-277-1251
ir@mongodb.com

Media Relations
MongoDB PR
press@mongodb.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mongodb-inc-to-present-at-the-27th-annual-needham-growth-conference-302347475.html

SOURCE MongoDB, Inc.

Continue Reading

Trending